axlr_logo-2022_HD_bleudeprusseaxlr_logo-2022_HD_bleudeprusseaxlr_logo-2022_HD_bleudeprusseaxlr_logo-2022_HD_bleudeprusse

  • SATT AxLR
    • SATT AxLR
    • Governance
    • Services for companies
    • Annual reports
  • Assisting you
    • Researchers
      • Call-for-projects
    • Companies
    • Startups
    • Practical guide
  • Technology offerings
    • Invest
      • In our technologies
      • In our startups
    • Technologies
    • Startups
    • AxLR TV
  • Working with AxLR
    • Purchasing & public procurement
    • Join us
    • Our startups are hiring
  • Media
    • News
    • Agenda
    • Press kit
    • Communication kit
  • Contact
English
  • French
✕
  • Home
  • PL-VAC
CAPDCM
13 October 2019
ALPHA-CENTAURI
12 October 2019

PL-VAC

PL-VAC

PAN-LEISHMANIASIS PROPHYLACTIC HUMAN VACCINE

Technologie disponible

Desired partnership(s)

  • Licensing

IP

  • Patent

Establishment(s)

  • IRD
  • CIRAD
  • Institut Pasteur, Tunisia

Keywords

  • Leishmanioses
  • Secretomes
  • Multi-epitope peptide vaccine

Context

Leishmaniasis is considered to be one of the most serious parasitic infections affecting humans worldwide and represents a major public health concern in Latin America, Asia, Africa, and southern Europe.

Benefits

The team identified a cocktail of multi-epitope peptides that activate the immune system specifically to fight different species of Leishmania.

Applications

This project seeks to develop a new prophylactic vaccine solution against leishmaniasis to provide optimal vaccination coverage for the population, notably in southern countries and countries developing as a result of migration and military flows.

AVAILABLE TECHNOLOGY | Leishmanioses – Secretomes – Multi-epitope peptide vaccine

Share
0

Related posts

8 September 2021

StabCFTR


En savoir +
6 July 2021

HTLV-1


En savoir +
23 June 2021

GEOSOTECH


En savoir +
© 2023, AxLR - SATT Occitanie Méditerranée. All rights reserved. | Legal terms & Privacy policy
English
  • English
  • French